Oral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy

Journal of Oral Pathology and Medicine

Volumn 42, Issue 1, 2013, Pages 53-60

  Nittayananta, Wipawee ^a   Kemapunmanus, Marisa ^a   Amornthatree, Korntip ^a   Talungchit, Sineepat ^b   Sriplung, Hutcha ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; Defensins; HBD2; HIV; Oral health; Oral lesion; Risk factor; Saliva

Indexed keywords

BETA DEFENSIN 2; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CHEEK MUCOSA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MOUTH EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SALIVA ANALYSIS;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-DEFENSINS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; MALE; MIDDLE AGED; MOUTH MUCOSA; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALIVARY PROTEINS AND PEPTIDES; STATISTICS, NONPARAMETRIC; VIRAL LOAD; YOUNG ADULT;

EID: 84871937661     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2012.01183.x     Document Type: Article

References (35)

1. Challacombe SJ, Naglik JR. The effects of HIV infection on oral mucosal immunity. Adv Dent Res 2006; 19: 29-35.
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society USA panel. JAMA 2008; 300: 555-70.
3. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immune-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299-304.
4. Nokta M. Oral manifestations associated with HIV infection. Curr HIV/AIDS Rep 2008; 5: 5-12.
5. Miziara ID, Weber R. Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children. J Oral Pathol Med 2008; 37: 99-106.
6. Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 2007; 48: 215-23.
7. Clifford GM, Polesel J, Rickenbach M, et al. Cancer Risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
8. Gillison ML. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 2009; 21: 439-44.
9. Dale BA, Fredericks LP. Antimicrobial peptides in the oral environment: expression and function in health and disease. Curr Issues Mol Biol 2005; 7: 119-33.
10. Zhao C, Wang I, Lehrer R. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996; 396: 319-22.
11. Mathews M, Jia H, Guthmiller J, et al. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999; 67: 2740-5.
12. Krisanaprakornkit S, Weinberg A, Perez C, Dale B. Expression of the peptide antibiotic human beta defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect Immun 1998; 66: 4222-8.
13. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-20.
14. Joly S, Compton LM, Pujol C, Kurago ZB, Guthmiller JM. Loss of human beta-defensin 1, 2, and 3 expression in oral squamous cell carcinoma. Oral Microbiol Immunol 2009; 24: 353-60.
15. Kesting MR, Loeffelbein DJ, Hasler RJ, et al. Expression profile of human beta-defensin 3 in oral squamous cell carcinoma. Cancer Invest 2009; 27: 575-81.
16. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993; 22: 289-91.
17. Nittayananta W, Talungchit S, Jaruratanasirikul S, et al. Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med 2010; 39: 397-406.
18. Kimball JR, Nittayananta W, Klausner M, Chung WO, Dale BA. Antimicrobial barrier of an in vitro oral epithelial model. Arch Oral Biol 2006; 51: 775-83.
19. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2010, http://www.R.project.org/.
20. Challacombe SJ, Sweet SP. Oral mucosal immunity and HIV infection: current status. Oral Dis 2002; 8(Suppl 2): 55-62.
21. Laskaris G, Hadjivassiliou M, Stratigos J. Oral signs and symptoms in 160 Greek HIV-infected patients. J Oral Pathol Med 1992; 21: 120-3.
22. Glick M, Muzyka BC, Lurie D, Salkin LM. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994; 77: 344-9.
23. Nittayananta W, Chungpanich S. Oral lesions in a group of Thai people with AIDS. Oral Dis 1997; 3(Suppl. 1): 1-5.
24. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010; 170: 1337-45.
25. Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep 2008; 5: 140-9.
26. Adler DH. The impact of HAART on HPV-related cervical disease. Curr HIV Res 2010; 8: 493-7.
27. McCullough M, Jaber M, Barrett AW, Bain L, Speight PM, Porter SR. Oral yeast carriage correlates with presence of oral epithelial dysplasia. Oral Oncol 2002; 38: 391-3.
28. Field EA, Field JK, Martin MV. Does Candida have a role in oral epithelial neoplasia?J Med Vet Mycol 1989; 27: 277-94.
29. Diamond G, Ryan L. Beta-defensins: what are they really doing in the oral cavity?Oral Dis 2011; 17: 628-35.
30. Schaaij-Visser TB, Bremmer JF, Braakhuis BJ, et al. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Oral Oncol 2010; 46: 123-7.
31. White JS, Weissfeld JL, Ragin C, et al. The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol 2007; 43: 701-12.
32. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5: 127-35.
33. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the international agency for research on cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-83.
34. Mork J, Lie AK, Glattre E, Hallmans G, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-31.
35. Amornthatree K, Sriplung H, Mitarnun W, Nittayananta W. Impacts of long-term use of antiretroviral therapy on the prevalence of oral human papilloma virus type 16. J Oral Pathol Med 2012; 41: 309-14.